1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Oramed Failure Highlights Insurmountable Challenge Of Oral Insulin Delivery

Israeli Firm's Candidate Suffers Phase III Flop

 
• By Kevin Grogan

Oramed's attempts to advance an oral formulation of insulin for type 2 diabetes patients have been scuppered with a Phase III fail that has sunk the stock.

Insulin wireframe of syringe and vial
Attempts to replace injections of insulin with a more convenient delivery method have failed miserably • Source: Shutterstock

Oramed Pharmaceuticals Inc. has joined the list of companies that have fallen short in the development of an oral formulation of insulin and the failure of ORMD-0801 in a late-stage diabetes trial has resulted in the Israeli firm's share price falling to the floor.

NASDAQ-listed Oramed announced topline results from a Phase III trial which compared ORMD-0801 with placebo in 710 patients with type 2 diabetes with inadequate glycemic control who were on two or three oral glucose-lowering agents

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.